Effects of stimulant medication on growth rates across 3 years in the MTA follow-up.

OBJECTIVE To evaluate the hypothesis of stimulant medication effect on physical growth in the follow-up phase of the Multimodal Treatment Study of Children With ADHD. METHOD Naturalistic subgroups were established based on patterns of treatment with stimulant medication at baseline, 14-, 24-, and 36-month assessments: not medicated (n = 65), newly medicated (n = 88), consistently medicated (n = 70), and inconsistently medicated (n = 147). Analysis of variance was used to evaluate effects of subgroup and assessment time on measures of relative size (z scores) obtained from growth norms. RESULTS The subgroup x assessment time interaction was significant for z height (p <.005) and z weight (p <.0001), due primarily to divergence of the newly medicated and the not medicated subgroups. These initially stimulant-naïve subgroups had z scores significantly >0 at baseline. The newly medicated subgroup showed decreases in relative size that reached asymptotes by the 36-month assessment, when this group showed average growth of 2.0 cm and 2.7 kg less than the not medicated subgroup, which showed slight increases in relative size. CONCLUSIONS Stimulant-naïve school-age children with Combined type attention-deficit/hyperactivity disorder were, as a group, larger than expected from norms before treatment but show stimulant-related decreases in growth rates after initiation of treatment, which appeared to reach asymptotes within 3 years without evidence of growth rebound.

[1]  J. Swanson,et al.  Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects. , 2007, Journal of the American Academy of Child and Adolescent Psychiatry.

[2]  Kimberly Hoagwood,et al.  Secondary evaluations of MTA 36-month outcomes: propensity score and growth mixture model analyses. , 2007, Journal of the American Academy of Child and Adolescent Psychiatry.

[3]  Robert D Gibbons,et al.  3-year follow-up of the NIMH MTA study. , 2007, Journal of the American Academy of Child and Adolescent Psychiatry.

[4]  J. Swanson,et al.  Stimulant-related reductions of growth rates in the PATS. , 2006, Journal of the American Academy of Child and Adolescent Psychiatry.

[5]  S. Pliszka,et al.  Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder. , 2006, Journal of the American Academy of Child and Adolescent Psychiatry.

[6]  S. Faraone,et al.  Does prolonged therapy with a long-acting stimulant suppress growth in children with ADHD? , 2006, Journal of the American Academy of Child and Adolescent Psychiatry.

[7]  J. Swanson,et al.  The services for children and adolescents-parent interview: development and performance characteristics. , 2004, Journal of the American Academy of Child and Adolescent Psychiatry.

[8]  J. Severe,et al.  Reliability of the services for children and adolescents-parent interview. , 2004, Journal of the American Academy of Child and Adolescent Psychiatry.

[9]  R. Schachar,et al.  Stimulant treatment over five years: adherence, effectiveness, and adverse effects. , 2004, Journal of the American Academy of Child and Adolescent Psychiatry.

[10]  J. Swanson,et al.  National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. , 2004, Pediatrics.

[11]  J. Swanson,et al.  A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). , 2004, Pediatrics.

[12]  J. Swanson,et al.  Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD. , 2003, Journal of the American Academy of Child and Adolescent Psychiatry.

[13]  M. Monuteaux,et al.  Growth deficits and attention-deficit/hyperactivity disorder revisited: impact of gender, development, and treatment. , 2003, Pediatrics.

[14]  A. Poulton,et al.  Slowing of growth in height and weight on stimulants: A characteristic pattern , 2003, Journal of paediatrics and child health.

[15]  J. Swanson,et al.  Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. , 2003, Archives of general psychiatry.

[16]  A. Gjedde,et al.  Methylphenidate‐Evoked Potentiation of Extracellular Dopamine in the Brain of Adolescents with Premature Birth , 2002, Annals of the New York Academy of Sciences.

[17]  M. Weissman,et al.  National trends in the use of psychotropic medications by children. , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

[18]  J. Swanson,et al.  Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: Therapeutic implications , 2002, Synapse.

[19]  J. Swanson,et al.  A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. , 2002, Pediatrics.

[20]  L. Greenhill,et al.  Practice Parameter for the Use of Stimulant Medications in the Treatment of Children, Adolescents, and Adults , 2002 .

[21]  J. Swanson,et al.  Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. , 2001, Pediatrics.

[22]  J. Swanson,et al.  Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.

[23]  H. Kraemer,et al.  Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.

[24]  L. Ponto,et al.  Predictors of adult height and weight in boys treated with methylphenidate for childhood behavior problems. , 2000, Journal of the American Academy of Child and Adolescent Psychiatry.

[25]  Stephen P. Hinshaw,et al.  A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. , 1999, Archives of general psychiatry.

[26]  N. Volkow,et al.  Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D(2) receptors. , 1999, The Journal of pharmacology and experimental therapeutics.

[27]  I. Shoulson,et al.  Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children , 1999, Clinical pharmacology and therapeutics.

[28]  J A Cipkala-Gaffin,et al.  Diagnosis and treatment of attention-deficit/hyperactivity disorder. , 1998, Perspectives in psychiatric care.

[29]  C. Gillberg,et al.  Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomized, double-blind, placebo-controlled trial. , 1997, Archives of general psychiatry.

[30]  H. Kraemer,et al.  National Institute of Mental Health Collaborative Multimodal Treatment Study of Children with ADHD (the MTA). Design challenges and choices. , 1997, Archives of general psychiatry.

[31]  W. Wetsel,et al.  Anterior Pituitary Hypoplasia and Dwarfism in Mice Lacking the Dopamine Transporter , 1997, Neuron.

[32]  S. Faraone,et al.  Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays? , 1996, Journal of the American Academy of Child and Adolescent Psychiatry.

[33]  J. Swanson,et al.  More frequent diagnosis of attention deficit-hyperactivity disorder. , 1995, The New England journal of medicine.

[34]  R. Klein,et al.  Hyperactive boys almost grown up. III. Methylphenidate effects on ultimate height. , 1988, Archives of general psychiatry.

[35]  D. Klein,et al.  Methylphenidate and growth in hyperactive children. A controlled withdrawal study. , 1988, Archives of general psychiatry.

[36]  R. Gittelman,et al.  Growth of hyperactive children on maintenance regimen of methylphenidate. , 1983, Archives of general psychiatry.

[37]  J. Overall,et al.  The effects of stimulant medication on the growth of hyperkinetic children. , 1979, Pediatrics.

[38]  A. Schell,et al.  Growth of hyperactive children treated with methylphenidate. , 1979, Archives of general psychiatry.

[39]  D. Safer,et al.  Depression of growth in hyperactive children on stimulant drugs. , 1972, The New England journal of medicine.

[40]  J. Swanson,et al.  National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. , 2004, Pediatrics.

[41]  Thomas R. Riley,et al.  A Randomized Double-blind Placebo-controlled Trial , 2004 .

[42]  S. Rivkees,et al.  Daily Methylphenidate Use Slows the Growth of Children: A Community Based Study , 2003, Journal of pediatric endocrinology & metabolism : JPEM.

[43]  J. Swanson,et al.  Objective and subjective measures of the pharmacodynamic effects of Adderall in the treatment of children with ADHD in a controlled laboratory classroom setting. , 1998, Psychopharmacology bulletin.

[44]  M. Posner,et al.  Images of mind , 1994 .

[45]  K. Gadow,et al.  Psychosocial aspects of drug treatment for hyperactivity , 1981 .

[46]  D. Safer,et al.  Growth rebound after termination of stimulant drugs. , 1975, The Journal of pediatrics.